Bone marrow transplantation for myelodysplastic syndrome - Who? when? and which?

Bone Marrow Transplantation

Volumn 30, Issue 4, 2002, Pages 199-206

  Luger, S ^a   Sacks, N ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Allogeneic; Autologous; Myelodysplastic syndromes; Reduced intensity conditioning

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; METHOTREXATE; PENTOSTATIN; THIOTEPA;

AGE; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOTRANSPLANTATION; BLOOD TOXICITY; COMORBIDITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; PATIENT SELECTION; PRIORITY JOURNAL; SHORT SURVEY; SURVIVAL RATE; VEIN OCCLUSION; WHOLE BODY RADIATION; BONE MARROW TRANSPLANTATION; CLINICAL PROTOCOL; METHODOLOGY; REVIEW;

BONE MARROW TRANSPLANTATION; CLINICAL PROTOCOLS; HUMANS; MYELODYSPLASTIC SYNDROMES; TRANSPLANTATION CONDITIONING;

EID: 0036676069     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703610     Document Type: Short Survey

References (41)

1. The myelodysplastic syndromes
2. Proposals for the classification of the myelodysplastic syndromes
3. Recommendations for a morphologic, immunologic and cytogenetic (MIC) working classification of the primary and therapy related myelodysplastic disorders
4. International scoring system for evaluating prognosis in myelodysplastic syndromes
5. Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation
6. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the Chronic Leukaemia Working Party of the European Transplantation (EBMT)
7. Allogeneic bone marrow transplantation for myelodysplastic syndrome: Outcomes analysis according to IPSS score
8. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age
9. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome
10. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: A long-term study of 71 patients
11. Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy)
12. Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation
13. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors
14. Indications and timing of allogeneic bone marrow transplantation in myelodysplastic syndromes
15. Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation
16. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome
17. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: An EBMT survey
18. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high risk MDS, secondary or therapy related acute myelogenous leukemia
19. Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes
20. Successful peripheral blood stem cell transplantation for myelodysplastic syndrome
21. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukmiea following MDS
22. Unrelated donor marrow transplantation for myelodysplastic syndromes: Outcome analysis in 510 transplants facilitated by the National Marrow Donor Program
23. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes
24. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS
25. Phase I study of 131-I-Anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome
26. Successful donor lymphocyte infusion (DLI) in a patient with myelodysplastic syndrome (MDS) after failure of T-cell-depleted bone marrow transplantation (TD-BMT)
27. Donor lymphocyte infusion for a patient with relapsing myelodysplastic syndrome after allogeneic bone marrow transplantation
28. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
29. Donor leucocyte transfusions for relapse in myelodysplastic syndrome after allogeneic bone marrow transplantation
30. Adoptive immunotherapy with haploidentical allogeneic peripheral blood, lymphocytes following autologous bone marrow transplantation
31. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome
32. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome
33. Bone marrow transplantation for myelodysplasia
34. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: A long-term study of 70 patients - Report of the French Society of Bone Marrow Transplantation
35. Bone marrow transplantation for therapy-related myelodysplasia: Comparison with primary myelodysplasia
36. Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes
37. Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia
38. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia
39. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation
40. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia
41. A novel preparative regimen associated with reduced morbidity and mortality following allogeneic bone marrow transplant